
Abbott


Working at Abbott
Company Summary
Overall Rating

5% above

Highly rated for 
Company culture, Salary, Work-life balance

Critically rated for
Promotions
Work Policy




Top Employees Benefits
Rate your company
🤫 100% anonymous
How was your last interview experience?
About Abbott

CREATING LIFE-CHANGING TECHNOLOGY
At Abbott, we’re dedicated to helping people live more fully, in everything we do. We’re creating the future of healthcare through life-changing technologies and products that make you healthier and stronger, quickly identify when you have a medical need, and treat conditions to help you get back to doing what you love.
With headquarters in north suburban Chicago, we serve people in more than 160 countries with leading medical devices, diagnostics, nutrition products, and branded generic medicines. Our 114,000 colleagues are helping millions of people to live better and healthier, every day around the world.
Medicine
AmbitionBox Best Places to Work in India Awards
Abbott Ratings
Overall Rating
Category Ratings
Company culture
Salary
Work-life balance
Skill development
Job security
Work satisfaction
Promotions
Work Policy at Abbott
Abbott Reviews
Top mentions in Abbott Reviews
Compare Abbott with Similar Companies
![]() | ![]() Change Company | ![]() Change Company | ![]() Change Company | |
---|---|---|---|---|
Overall Rating | 4.1/5 based on 3.1k reviews ![]() | 4.0/5 based on 5.8k reviews ![]() | 4.1/5 based on 6.9k reviews ![]() | 5.0/5 based on 1 reviews |
Highly Rated for | Skill development Work-life balance Salary | Salary Skill development Job security | Skill development Salary Work-life balance | Skill development Work-life balance Salary |
Critically Rated for | Promotions | ![]() No critically rated category | ![]() No critically rated category | ![]() No critically rated category |
Primary Work Policy | Work from office 51% employees reported | Work from office 82% employees reported | Work from office 73% employees reported | - |
Rating by Women Employees | 4.0 Good rated by 387 women | 4.0 Good rated by 442 women | 4.1 Good rated by 681 women | - no rating available |
Rating by Men Employees | 4.2 Good rated by 2.5k men | 4.0 Good rated by 5k men | 4.1 Good rated by 5.8k men | - no rating available |
Job security | 3.8 Good | 3.8 Good | 3.7 Good | 4.0 Good |
Abbott Salaries
Territory Business Manager
Area Business Manager
Therapy Business Manager
Key Account Manager
Territory Sales Manager
Medical Representative
Area Sales Manager
Sales Development Manager
Territory Manager
Zonal Business Manager
Abbott Interview Questions
Interview questions by designation
Top Abbott interview questions and answers
Abbott Jobs
Abbott News
Stocks To Buy: Abbott India, Bajaj Finance, Bharat Forge, Chambal Fertilizers
- Analysts have buy calls on Abbott India, Bajaj Finance, Bharat Forge, and Chambal Fertilizers.
- Aditya Agarwal suggests a 'buy' for Abbott India with a target price of Rs 31,700 apiece.
- Aditya Agarwala has a buy call on Bajaj Finance with a target price of Rs 9,000.
- Reliance Securities' Vikas Jain recommends a 'buy' for Bharat Forge with a target price of Rs 1,170 apiece.

Optimus’ Linezolid Patent Revoked After Post-Grant Opposition
- The Indian Patent Office has revoked Patent No. 281489 held by Optimus after a post-grant opposition by Symed Labs.
- The patent was revoked due to lacking obviousness/inventive step and not being a patentable invention under section 3(d) and section 8 of the Patents Act.
- Linezolid, the subject of the patent, is an antibiotic used against pneumonia, skin infections, and drug-resistant tuberculosis.
- The drug is part of the National Pharmaceutical Pricing Authority's list with a fixed price, followed by a challenge by Abbott Healthcare, rejected in October 2024.
- The post-grant opposition process had several rounds of back and forth before a hearing took place in June 2024.
- Grounds for opposition included anticipation by prior publication, anticipation by prior claiming, obviousness, lack of inventive step, and not being a new invention.
- The patent office found that the claims were not anticipated by prior publication or claiming, but lacked inventive step and did not represent a new invention.
- The decision questioned the level of scrutiny by the patent office on procedural requirements like disclosure under section 8.
- The analysis focused on grounds like obviousness and non-patentability under section 3(d), highlighting the need for stringent examination in pharmaceutical patents.
- The opponent in the case, Symed Labs, had a history of litigating against patents related to Linezolid and specific infringement claims in the past.

RP Sanjiv Goenka Group elevates Janesh K to VP-group corporate HR
- RP Sanjiv Goenka Group has elevated Janesh K to the role of VP-group corporate HR.
- Janesh K moves from RP-SG FMCG (Guiltfree Industries) where he was CHRO since 2020.
- In his new role, Janesh will spearhead HR excellence initiatives and contribute to strategic HR programs.
- He will be based out of Kolkata.

A secretary turned $180 into $7.2 million by holding her employer's stock for 75 years
- Grace Groner, a secretary, bought three shares of her employer's stock for $60 in 1935.
- By reinvesting dividends for 75 years, her stake grew to $7.2 million.
- Groner gifted her entire fortune to a foundation supporting her alma mater.
- She maintained her modest lifestyle, living in a one-bedroom house and buying clothes from rummage sales.
From Abbott India, PVR Inox To Gujarat Gas And More: NSE To Exclude 16 Securities From F&O Effective Feb. 28
- The National Stock Exchange of India will exclude 16 securities, including Abbott India Ltd., PVR Inox Ltd., and Gujarat Gas Ltd., from the F&O market, effective Feb. 28, 2025.
- This exclusion is a result of revised guidelines from SEBI to increase liquidity standards.
- Existing unexpired contracts of the excluded securities will continue to be available for trading till their respective expiry.
- The updated criteria include higher thresholds for metrics such as median quarter sigma order size (MQSOS), minimum market-wide position limit (MWPL), and minimum average daily delivery value.

Trading Ideas: Don't Buy Axis Bank, NCC At Current Levels, Say Stock Market Experts
- Stock market experts advise against buying Axis Bank and NCC at current levels.
- Kushal Gandhi suggests avoiding Axis Bank as it has been on a downtrend with selling pressure sustaining.
- Sameer Dalal recommends buying NCC at lower levels, expecting a decent return over the next two years.
- Dalal advises investors to switch from Abbott India to Dr Reddy's Laboratories due to the latter's larger growth opportunity.

Abbott India Q2 Results: Profit Rises 15%, Beating Estimates
- Abbott India reported a net profit of Rs 359 crore, beating the consensus estimate of Rs 237 crore.
- Revenue increased by 9% to Rs 1,633 crore compared to the Bloomberg estimate of Rs 1,627 crore.
- Ebitda rose 15% to Rs 439 crore with a margin of 26.9%.
- Shares of Abbott India were trading 2.25% lower.

British house price growth slows more than expected; UK borrowing costs close to annual high after budget – business live
- British house price growth slows more than expected.
- UK borrowing costs close to annual high after budget.
- Reckitt Benckiser's shares surge 10% following a US court ruling on its baby formula subsidiary, Mead Johnson.
- Abbott and Reckitt unit Mead Johnson found not responsible for a young boy's intestinal disease in a lawsuit victory.
Abbott Subsidiaries
Abbott Diabetes Care
Abbott Vascular
St. Jude Medical
Abbott Point of Care
Inverness Medical Innovations
Compare Abbott with




















Contribute & help others!
Companies Similar to Abbott










Abbott FAQs
Reviews
Interviews
Salaries
Users/Month